Inhibition of adaptive immune resistance is the mechanistic foundation of responses to PD-1 or PD-L1 inhibition [47, 48], which has made a significant contribution to the treatment of breast cancer [49, 50]. This evidence concerns the gene CD274 and breast carcinoma.